CYP19A1 and breast cancer: In this study, women with early breast cancer received either one of the aromatase inhibitors, anastrozole, exemestane, or letrozole, “upfront” for 5 years or a “switch” therapy regime of tamoxifen for 2 years and subsequently one of the three aromatase inhibitors for the following 3 years.